The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

HealthDay News — A new strain of bird flu, H5N9, has been detected for the first time in the US, raising concerns about how it continues to spread. The strain was discovered at a commercial duck farm ...

For patients with heart failure (HF), a greater focus on medication management may be needed in order to mitigate HF exacerbations caused by certain ...

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

“Beneficial pediatric obesity treatment response yielded enduring health benefits, markedly lowering future morbidity and mortality risks in young adulthood,” the authors write. Several authors ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

HealthDay News — Kansas health officials are tackling the largest tuberculosis (TB) outbreak in US history, with 67 confirmed cases since the start of 2025.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.